Unbound MEDLINE

A novel association between a chronic subdural hematoma and a fibrinolytic pathway defect: case report. Neurosurgery [Neurosurgery] Journal article

 
TitleA novel association between a chronic subdural hematoma and a fibrinolytic pathway defect: case report.
Author(s)Rughani AI, Holmes CE, Penar PL 
InstitutionDivision of Neurosurgery, University of Vermont, Burlington, Vermont 05401, USA. anand.rughani@vtmednet.org
SourceNeurosurgery 2009 Jun; 64(6):E1192; discussion E1192.
AbstractOBJECTIVE: Chronic subdural hematoma (CSDH) is a common form of intracranial hemorrhage that is known to recur in up to one-fifth of treated patients. We present a patient with recurrent CSDH who was found to have a defect in the fibrinolytic pathway, which may be a novel explanation for recurrent CSDH. This defect, deficiency of plasminogen activator inhibitor type I (PAI-1), should be recognized as a possible cause of CSDH.
CLINICAL PRESENTATION: A 49-year-old man presented with a CSDH, which recurred each time after 2 initially-effective craniotomies.
INTERVENTION: A deficiency of PAI-1 was diagnosed after the second recurrence. We hypothesize that this defect in the fibrinolytic system contributed to the recurrent hematoma. Treatment with aminocaproic acid led to resolution of the CSDH.
CONCLUSION: PAI-1 deficiency should be considered in patients with recurrent CSDH that lack another compelling explanation, particularly in patients with a family history of bleeding diatheses. PAI-1 deficiency can be identified by measuring plasma levels and can be treated with an oral course of aminocaproic acid.
Languageeng
Pub Type(s)Journal Article
PubMed ID19487862
  
Advertise on this site.